Protean BioDiagnostics Announces Launch of ROCHE PD-L1 (SP142) Assay as Part of its Breast Maps Package

image001 2.jpg

Protean BioDiagnostics is one of the first labs to make PD-L1 (SP142) testing available for breast cancer patients. Roche’s VENTANA PD-L1 (SP142) Assay was recently approved as a companion diagnostic assay to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane. Roche’s PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer. Each year about 300,000 women are diagnosed globally with triple-negative breast cancer, an aggressive disease with limited treatment options that represents 15 percent of all breast cancer cases

Protean BioDiagnostics, is committed to rapidly deploying practice changing diagnostic technologies and assays for community based cancer patients. Protean BioDiagnostics has created “Breast Maps” as an integrated testing solution for breast cancer patients and has added PDL1 testing to its integrated package.

Anthony Magliocco